Plasma compositions and methods of use thereof

Abstract

Provided herein are pathogen-inactivated plasma compositions and methods for treating a disease or condition using pathogen-inactivated plasma compositions.

1 . A method of treating a disease or condition indicated for treatment by plasma exchange in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of pathogen-inactivated plasma composition by plasma exchange, wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma. 
     
     
         2 . The method of  claim 1 , wherein the disease or condition is indicated for treatment with albumin by plasma exchange. 
     
     
         3 . The method of  claim 1 , wherein the disease or condition is other than thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS). 
     
     
         4 - 5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein the disease or condition is thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS). 
     
     
         7 - 10 . (canceled) 
     
     
         11 . The method of  claim 1 , wherein the pathogen-inactivated plasma composition is administered within 5 days after thawing. 
     
     
         12 . The method of  claim 1 , wherein the pathogen-inactivated plasma composition is a lyophilized or freeze-dried plasma composition. 
     
     
         13 - 66 . (canceled) 
     
     
         67 . The method of  claim 1 , wherein the plasma exchange is achieved with a volume of the plasma composition between about 1 times and about 1.5 times the subject's plasma volume. 
     
     
         68 . The method of  claim 1 , wherein the plasma exchange is achieved with a volume of the plasma composition comprising about 30 mL/kg, about 40 mL/kg, about 50 mL/kg, or about 60 mL/kg patient body weight. 
     
     
         69 . The method of  claim 1 , wherein the plasma exchange is performed at least two times. 
     
     
         70 . The method of  claim 69 , wherein the plasma exchange is performed 2-5 times. 
     
     
         71 . The method of  claim 69 , wherein the plasma exchange is performed 2-5 times within a period of two weeks. 
     
     
         72 . The method of  claim 1 , wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma prepared from one or more units of plasma from whole blood donation. 
     
     
         73 . The method of  claim 1 , wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma prepared from one or more plasma units from apheresis collected plasma. 
     
     
         74 . The method of  claim 1 , wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma prepared from one or more units of plasma that are subjected to pathogen inactivation within 24 hours of donation. 
     
     
         75 . The method of  claim 1 , wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma prepared from multiple plasma units. 
     
     
         76 . The method of  claim 1 , wherein the pathogen-inactivated cryo-poor plasma is prepared from plasma that is pathogen-inactivated by photochemical inactivation. 
     
     
         77 . The method of  claim 1 , wherein the pathogen-inactivated cryo-poor plasma is prepared from plasma that is pathogen-inactivated with a psoralen.